Basic Information

Gene symbol MAGEA12 Synonyms CT1.12, MAGE12 Type of gene protein-coding
Description MAGE family member A12

Gene symbol MAGEA3 Synonyms CT1.3, HIP8, HYPD, MAGE3, MAGEA6 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description MAGE family member A3

GTO ID GTC0106
Trial ID NCT01273181
Disease Melanoma | Retinal Cell Cancer | Metastatic Cancer
Altered gene MAGE-A3|MAGE-A12
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment MAGE-A3/12 TCR-T cells
HLAHLA-A*02:01
PhasePhase1|Phase2
Recruitment statusTerminated
TitlePhase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Year2011
CountryUnited States
Company sponsorNational Cancer Institute (NCI)
Other ID(s)110062|11-C-0062
Vector information
Vectorretrovirus
Vector typeγ-retroviral vector
Transgene/Inserted geneTCR α chain; linker peptide furinSGSGP2A; TCR β chain
Viral genome modificationMSGV-1 is derived from MSGV vector that utilizes the murine stem cell virus long terminal repeat and contains an extended gag region and Kozak sequence.

Clinical Result

Cohort1: dose level 1
Administration route infusion
Dosage 5E9 cells
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1/3(CR); 1/3(PR)
Adverse reactions 2/3(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; General disorders; Metabolism and nutrition disorders; Nervous system disorders; Respiratory, thoracic and mediastinal disorders)
References PMID: 23377668
Cohort2: dose level 2
Administration route infusion
Dosage 5E10 cells
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 2/3(PR)
Adverse reactions 1/3(Cardiac disorders; Cardiac disorders; Nervous system disorders)
References PMID: 23377668
Cohort3: dose level 3_Mel/RCC
Administration route infusion
Dosage maximum tolerated dose
Donor type autologous
Pts 2
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 0/2(ORR)
Adverse reactions 2/2(Nervous system disorders; Renal and urinary disorders)
References PMID: 23377668
Cohort4: dose level 3_Other Cancer
Administration route infusion
Dosage maximum tolerated dose
Donor type autologous
Pts 1
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 0/1(ORR)
Adverse reactions 1/1(General disorders)
References PMID: 23377668

Relationship Graph

Overview of Knowledge Graph